5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.07▲ | 1.04▲ | 1.02▲ | 0.95▲ | 1.05▲ |
MA10 | 1.05▲ | 1.00▲ | 0.99▲ | 0.93▲ | 0.94▲ |
MA20 | 1.01▲ | 0.99▲ | 0.98▲ | 1.01▲ | 0.71▲ |
MA50 | 0.99▲ | 0.95▲ | 0.94▲ | 0.90▲ | 0.82▲ |
MA100 | 0.95▲ | 0.98▲ | 1.01▲ | 0.71▲ | 1.03▲ |
MA200 | 0.99▲ | 1.07▲ | 1.03▲ | 0.78▲ | 1.33▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.010▲ | 0.011▲ | -0.009▼ | 0.057▲ |
RSI | 71.937▲ | 67.511▲ | 67.658▲ | 56.637▲ | 59.850▲ |
STOCH | 98.889▲ | 93.083▲ | 70.167 | 49.456 | 71.684 |
WILL %R | -5.000▲ | -4.000▲ | -4.000▲ | -9.677▲ | -26.362 |
CCI | 86.667 | 143.905▲ | 177.996▲ | 93.255 | 57.206 |
Thursday, August 14, 2025 10:08 AM
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic ...
|
Thursday, August 14, 2025 09:22 AM
USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment ...
|
Wednesday, August 13, 2025 05:45 AM
Lake Street analyst Chad Messer initiated coverage of Oncolytics (ONCY) with a Buy rating and $7 price target Oncolytics is emerging under new ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 0.9588 | 1.09 | 0.94 | 1.08 | 876,168 |
14/08/25 | 0.98 | 1.0199 | 0.94 | 0.9403 | 700,165 |
13/08/25 | 0.86 | 1.065 | 0.86 | 1.02 | 1,363,766 |
12/08/25 | 0.83 | 0.8749 | 0.83 | 0.8603 | 531,019 |
11/08/25 | 0.84 | 0.89 | 0.8204 | 0.8676 | 357,563 |
08/08/25 | 0.95 | 0.95 | 0.83 | 0.8584 | 992,357 |
07/08/25 | 0.93 | 0.9893 | 0.8801 | 0.9151 | 548,684 |
06/08/25 | 0.92 | 0.976 | 0.8901 | 0.93 | 334,389 |
05/08/25 | 0.875 | 1.01 | 0.86 | 0.95 | 1,144,071 |
04/08/25 | 0.99 | 0.99 | 0.80 | 0.8831 | 1,101,802 |
|
|
||||
|
|
||||
|
|